DMMR Cancer clinical trials at UCSF

1 research study open to eligible people

DMMR cancer is caused by faulty DNA repair in cells. At UCSF, a study is exploring an IL-2 therapy to see if it can help the body attack cancer. The trial aims to find out how safe this treatment is and its impact on cancer cells.

Showing trials for

  • Beta-only IL-2 ImmunoTherapY Study

    open to eligible people ages 18 years and up

    This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

    San Francisco, California and other locations

Last updated: